Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication

Table 3 Correlation of subjective well-being and drug attitude with symptomatology and global functioning. Spearman rank correlation

			PANSS positive	PANSS negative	PANSS general	PANSS total	GAF	DAI total
Week 2	SWN-K total	r Spearman (p-value)	−.274 (.143)	−.323 (.082)	−.419^* (.021)	−.375^* (.041)	.559^** (.001)	.196 (.299)
	DAI total	r Spearman (p-value)	−.017 (.93)	−.095 (.616)	−.206 (.276)	−.197 (.297)	−.006 (.976)	-
Week 4	SWN-K total	r Spearman (p-value)	−.415^* (.022)	−.235 (.210)	−.441^* (.015)	−.480^** (.007)	.642^** (.000)	.128 (.5)
	DAI total	r Spearman (p-value)	.084 (.66)	.161 (.394)	.09 (.637)	.19 (.314)	−.203 (.283)	-
Week 12	SWN-K total	r Spearman (p-value)	−.238 (.205)	−.238 (.206)	−.324 (.081)	−.318 (.087)	.576** (.001)^a	.068 (.727)^a
	DAI total	r Spearman (p-value)	−.069 (.721)^a	−.102 (.598)^a	−.095 (.625)^a	−.114 (.555)^a	−.095 (.63)^b	-

SWN-K = Subjective Well-being under Neuroleptic Treatment Scale, short form; PANSS = Positive and Negative Syndrome Scale; DAI = Drug Attitude Inventory
^aN = 29
^bN = 28

ISSN: 1471-244X